Journal of Physiology & Pathology in Korean Medicine
/
v.25
no.2
/
pp.257-263
/
2011
This study was designed to investigate the effects of Hominis placenta pharmacopuncture treatment and electroacupuncture therapy on the functional recovery and histological change, protein expression in spinal cord injury(SCI) rats. Experimental groups were divided into the Group I(normal control rat), Group II(Non-treatment after spinal cord injury induction), Group III(Hominis placenta pharmacopuncture treatment after SCI induction), Group IV (Electroacupuncture therapy after SCI induction), Group V(Hominis placenta pharmacopuncture treatment and electroacupuncture therapy after SCI induction). After operation, rats were tested at modified Tarlov test at 1 to 3 days with divided into 4 groups, and motor behavior test(BBB locomotor rating scale, Grid walk test) was examined at 3, 7, 14, and 21 days. For the observation of damage change and size of the organized surface in muscle and spinal cord, histopathological studies were performed at 21 days by H & E stain, and BDNF & NT-3 protein expression studies were performed at 21 days. Acco rding to the results, Hominis placenta pharmacopuncture treatment and electroacupuncture therapy can play a role in facilitating recovery of locomotion following spinal cord injury. Specially, Hominis placenta pharmacopuncture treatment and electroacupuncture combimed therapy after SCI induction was most improvement in functional recovery, BDNF, and NT-3 protein synthesis.
Objectives: The purpose of this review is to analyze the domestic study trends on climacteric syndrome treated with pharmacopuncture. Methods: We investigated the studies on pharmacopuncture for climacteric syndrome via searching 6 online databases. Results: 18 studies were selected. There were 2 case reports, 1 randomised controlled trial, and 15 animal experiments. There were 14 studies about osteoporosis, 1 study about hot flush and sweating, 1 study about abdominal obesity, 1 study about neck pain, and 1 study about learning disability and memory disorder. Nokyong was most frequently used for pharmacopuncture, followed by Honghwa. 陰谷 (KI10) was most frequently used for acupuncture point, followed by 腎兪 (BL23). Conclusions: This study shows that pharmacopuncture could be one of the effective treatments for climacteric syndrome. More well-designed clinical studies using pharmacopuncture for climacteric syndrome will be needed.
Objectives: The purpose of this study was to research the trend related to pharmacopuncture for insomnia in China for further development of pharmacopuncture in Korea. Methods: This study reviewed and analyzed 21 Chinese journals related to pharmacopuncture 2013~2019 sourced with the following keywords in the China National Knowledge Infrastructure (CNKI). 'Shimian', 'Wuewei zhushe', 'Shuizhen', 'Xuewei yaowu zhushe', 'Yaowu xuewei zhushe', 'Xuewei zhuyao', 'Xuezhu', and 'Xueweiyaowu zhuru'. Results: The following results were obtained in this study. 1. A total of 21 papers were selected, comprised of clinical research and case reports. 2. Pharmacopuncture was often used for insomnia, and as the medicine of injection, Salvia, Gastrodin, Acanthopanax, Hominis Placenta, Qingkailing, Shenmai, Bozhi Glycopeptide, Fufang Danggui, Vitamin B12, and Chlorpromazine Hydrochloride were used. 3. In combined treatments, acupuncture, chiropractic, auricular sticking, and herbal medicine were used. 4. It was more effective compared to conservational acupuncture therapy. Conclusions: It was established that they have efficiency to treat insomnia with pharmacopuncture in China, but there were limitations in this study, so we need more research to identify new medicines for neuropsychiatric diseases.
Jeong Ho Huh;Dong Heon Lee;Jun Young Lee;Ju Hwa Jeong;Seok Hee Kim;Kyung Jin Lee;Tae Han Yook;Kyeong Han Kim
Journal of Pharmacopuncture
/
v.26
no.1
/
pp.99-104
/
2023
Our study purpose was to report the clinical application of five different pharmacopunctures (Sweet BV, Scolopendrae Corpus, Chukyu, Cervi Parvum Cornu, and Hominis Placenta) for trigger finger. A patient was admitted to Ba-reun-mom S Korean Medicine Clinic and diagnosed with trigger finger. Because the effects of each pharmacopuncture have been confirmed in various acute to chronic cases, we treated a patient diagnosed with trigger finger using pharmacopunctures Sweet BV and Scolopendrae Corpus at the acute phase, Chukyu pharmacopuncture at the acute to chronic phase, and pharmacopunctures Cervi Parvum Cornu and Hominis Placenta at the chronic phase. This case was measured and assessed by Quinnell's classification of triggering and visual analogue scale (VAS) scores. After treatment, the patient's fifth finger pain and function were improved. The VAS score decreased from 5 to 0. The Quinnell's classification of triggering score decreased from 2 to 0. This case indicated that a patient with trigger finger could be treated by five pharmacopuncture treatments according to the treatment regimen and disease progress.
Objectives : This study was aimed at comparing clinical effectiveness among pharmacopuncture treatment, Chuna treatment, pharmacopuncture-Chuna cooperative treatment for neck pain caused by traffic accidents. Methods : This study was carried out on the 87 patients with neck pain caused by traffic accidents. The patients were divided into 3 groups ; group A was treated with pharmacopuncture. group B was treated with Chuna treatment. group C was treated with pharmacopuncture and Chuna cooperative treatment one at a time. Also all groups were treated with general acupuncture and herb-medicine treatment. We measured visual analog scale(VAS) and neck disability index(NDI) before the treatment and 2, 4 weeks later. Results : In result each group had significant decrease in VAS and NDI after 4 weeks later. group C showed significant difference as compared to group A and B in NDI and VAS scores. In the first period(from pre to 2 weeks treatment) group C showed significant difference as compared to group A and B in VAS scores. Conclusions : According to the results of this study, it was suggested that chuna treatment and pharmacopuncture are effective in reducing neck pain caused by traffic accidents. Pharmacopuncture and Chuna cooperative treatment was more effective in reducing neck pain caused by traffic accidents. Especially in the first period(from pre to 2 weeks treatment) pharmacopuncture-Chuna cooperative treatment was more effective than pharmacopuncture treatment, Chuna treatment for neck pain caused by traffic accidents.
Jo, Dong-Chan;Lee, Jin-Hyun;Kim, Chang-Gon;Jung, Woo-Seok;Moon, Su-Jeong;Park, Tae-Yong;Lee, Jung-Han
Journal of Korean Medicine Rehabilitation
/
v.23
no.4
/
pp.73-82
/
2013
Objectives The purpose of this review is to investigate studies of Scolopendrid pharmacopuncture and the evidence of it's effects in order to suggest a better research method in the future. Methods We retrieved numbers of clinical studies about Scolopendrid pharmacopuncture from 7 Korean web databases, using key words such as 'Scolopendrid', 'Scolopendrid AND Pharmacopuncture'. This study had been conducted from 1st May 2013 to 31th July 2013. Controlled studies and case studies were only used for this study. Clinical studies that we picked from the databases were classified according to the diseases that those studies are about, and from these clinical studies, we are to research what has to be improved generally in clinical researches. Results 18 case studies, 4 controlled studies had been under research. Scolopendrid pharmacopuncture has a therapeutic effect mainly in musculoskeletal and neurological diseases such as herniated intervertebral disc, carpal tunnel syndrome, swollen leg, feeling of cold on legs, wrist ganglion, lateral epicondylitis, radial nerve palsy, cervical myelopathy, cauda equina syndrome, postauricular pain; as an early symptom of Bell's palsy, pain of popliteal part, gout, plantar fasciitis, cellulitis, frozen shoulder, pain of hip adductors. However objectivity and reliability of the Scolopendrid pharmacopuncture studies still remains controversial. Conclusions It has been suggested that there are positive effects of Scolopendrid pharmacopuncture therapy in treating specific diseases (especially neuromusculoskeletal diseases). However, this narrative review can't conclude and prove that the Scolopendrid pharmacopuncture has positive effectiveness on these diseases unlike systematic review. So, in order to put Scolopendrid pharmacopuncture therapy to use for many kinds of diseases in more reasonable ways, it is essential to build well-designed clinical research tools. In the future, abundant case studies, more follow-up trials and randomized controlled trials based on the korean medicine should be done to use Scolopendrid pharmacopuncture for a clinical purpose.
Objectives : The purpose of this study is to compare the effects of Hwangryunhaedok-tang pharmacopuncture therapy with Hominis Placenta pharmacopncture therapy in hospitalized patients with peripheral facial paralysis. Methods : We investigated 34 cases of patients with peripheral facial paralysis who were admitted into the Dept. of Acupuncture & Moxibustion of Dongshin University Suncheon Oriental Hospital from February 1, 2014 to June 31, 2015. Subjects were divided into two groups, Hwangryunhaedok-tang pharmacopuncture group(HR group), and Hominis Placenta Pharmacopuncture group(JH group). HR group was treated by Hwangryunhaedok-tang pharmacopuncture five times a week and JH group was treated by Hominis Placenta Pharmacopuncture five times a week. And both groups were treated by acupuncture, electroacupuncture, herbal medicine therapy, western drug therapy equally. To investigate the effectiveness of treatment, we used House-Brackmann Grading System, Yanagihara's unweighted grading system and Sunnybrook facial grading scale at before admission and after admission. Results : Each scores by 3 evaluation methods improved both in two groups. However, there were no significant differences in improvement between two groups. Conclusions : These results suggest that the Hwangryunhaedok-tang pharmacopuncture therapy is as effective as Hominis Placenta pharmacopuncture therapy to improve symptoms of peripheral facial paralysis.
Woenhyung Lee;Hyeonjun Woo;Yunhee Han;Seungkwan Choi;Jungho Jo;Byeonghyeon Jeon;Wonbae Ha;Junghan Lee
Journal of Korean Medicine Rehabilitation
/
v.33
no.4
/
pp.31-44
/
2023
Objectives The purpose of this study is to check the research trends of pharmacopuncture treatment in nerve entrapment syndrome, identify specific techniques, identify which pharmacopuncture are used, and provide directions for future research. Methods This study was conducted based on the five steps suggested by Arksey and O'Malley. We searched five domestic databases (Research Information Sharing Service, Oriental Medicine Advanced Searching Integrated System, Korean studies Information Service System, Science ON, and KMBASE) and identified studies with key search terms like "nerve entrapment" And "pharmacopuncture" until June 23, 2023. Results Twenty-nine studies were finally selected. among them, 25 papers were non-comparative studies (86.2%). The most common disease was carpal tube syndrome (n=10). All the investigated studies were treated by injecting pharmacopuncture into the pathway of the entraped nerve. The depth of pharmacopuncture injection was mentioned only in 13 studies. As for the pharmacopuncture used, sweet bee venom was 8 studies and bee venom was 6 studies, and about half of the pharmacopuncture manufactured with Bee venom as the main component accounted for. Conclusions This study is a scoping review of the pharmacopuncture treatment for nerve entrapment, which was first conducted in Korea. The treatment is mainly performed on the path way of the entraped nerve. After that, it is necessary to study the standardization of the specific technique method of pharmacopuncture and the uniformity of evaluation criteria.
Objectives: This study was performed to analyze single dose toxicity and the lethal dose of Scolopendrid Pharmacopuncture in rats. Methods: All experiments were conducted at the Korea Testing & Research Institute (KTR), an institution authorized to perform non-clinical studies, under the regulations of Good Laboratory Practice (GLP). Sprague-Dawley rats were chosen for the pilot study. Doses of Scolopendrid pharmacopuncture, 0.1, 0.5, and 1.0 mL, were administered to the experimental group, and 1.0 mL doses of normal saline solution were administered to the control group. This study was conducted under the approval of the Institutional Animal Ethic Committee. Results: No deaths or abnormalities occurred in any of the groups. No significant changes in the weight, hematological parameters or clinical chemistry were noted between the control group and the experimental group. To check for abnormalities in organs and tissues, we used microscopy to examine representative histological sections of each specified organ; the results showed no significant differences in any of the organs or tissues. Conclusion: The above findings suggest Scolopendrid Pharmacopuncture is a relatively safe to use for treatment. Further studies on the subject should be conducted to yield more concrete evidence.
Objectives: Mountain ginseng pharmacopuncture (MGP) is a pharmacopuncture made by distilling extract from mountain cultivated ginseng or mountain wild ginseng. This pharmacopuncture is injected intravenously, which is a quick, lossless way of strongly tonifying Qi function. The present study was undertaken to evaluate a 4-week, repeated, intravenous injection, toxicity test of MGP in Sprague-Dawley (SD) rats. Methods: Twenty male and female 6-week-old SD rats were used as subjects. We divided the SD rats into 4 groups: the high-dosage (10 mL/kg), medium-dosage (5 mL/kg), low-dosage (2.5 mL/kg) and control (normal saline) groups. MGP or normal saline was injected intravenously into the caudal vein of the rats once daily for 4 weeks. Clinical signs, body weights, and food consumption were monitored during the observation period, and hematology, serum biochemistry, organ weight, necropsy, and histological examinations were conducted once the observations had been completed. Results: No mortality was observed in any of the groups during the observation period. No changes due to MGP were observed in the experimental groups regarding clinical signs, body weights, food consumption, hematology, serum biochemistry, organ weight and necropsy. No histological changes due to MGP were observed in any of the male or female rats in the high-dosage group. Conclusion: During this 4-week, repeated, intravenous injection, toxicity test of MGP in SD rats, no toxic changes due to MGP were observed in any of the male or female rats in the high-dosage group. Thus, we suggest that the high and the low doses in a 13-week, repeated test should be 10 mL/kg and 2.5 mL/kg, respectively.
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며,
이를 위반시 정보통신망법에 의해 형사 처벌됨을 유념하시기 바랍니다.
[게시일 2004년 10월 1일]
이용약관
제 1 장 총칙
제 1 조 (목적)
이 이용약관은 KoreaScience 홈페이지(이하 “당 사이트”)에서 제공하는 인터넷 서비스(이하 '서비스')의 가입조건 및 이용에 관한 제반 사항과 기타 필요한 사항을 구체적으로 규정함을 목적으로 합니다.
제 2 조 (용어의 정의)
① "이용자"라 함은 당 사이트에 접속하여 이 약관에 따라 당 사이트가 제공하는 서비스를 받는 회원 및 비회원을
말합니다.
② "회원"이라 함은 서비스를 이용하기 위하여 당 사이트에 개인정보를 제공하여 아이디(ID)와 비밀번호를 부여
받은 자를 말합니다.
③ "회원 아이디(ID)"라 함은 회원의 식별 및 서비스 이용을 위하여 자신이 선정한 문자 및 숫자의 조합을
말합니다.
④ "비밀번호(패스워드)"라 함은 회원이 자신의 비밀보호를 위하여 선정한 문자 및 숫자의 조합을 말합니다.
제 3 조 (이용약관의 효력 및 변경)
① 이 약관은 당 사이트에 게시하거나 기타의 방법으로 회원에게 공지함으로써 효력이 발생합니다.
② 당 사이트는 이 약관을 개정할 경우에 적용일자 및 개정사유를 명시하여 현행 약관과 함께 당 사이트의
초기화면에 그 적용일자 7일 이전부터 적용일자 전일까지 공지합니다. 다만, 회원에게 불리하게 약관내용을
변경하는 경우에는 최소한 30일 이상의 사전 유예기간을 두고 공지합니다. 이 경우 당 사이트는 개정 전
내용과 개정 후 내용을 명확하게 비교하여 이용자가 알기 쉽도록 표시합니다.
제 4 조(약관 외 준칙)
① 이 약관은 당 사이트가 제공하는 서비스에 관한 이용안내와 함께 적용됩니다.
② 이 약관에 명시되지 아니한 사항은 관계법령의 규정이 적용됩니다.
제 2 장 이용계약의 체결
제 5 조 (이용계약의 성립 등)
① 이용계약은 이용고객이 당 사이트가 정한 약관에 「동의합니다」를 선택하고, 당 사이트가 정한
온라인신청양식을 작성하여 서비스 이용을 신청한 후, 당 사이트가 이를 승낙함으로써 성립합니다.
② 제1항의 승낙은 당 사이트가 제공하는 과학기술정보검색, 맞춤정보, 서지정보 등 다른 서비스의 이용승낙을
포함합니다.
제 6 조 (회원가입)
서비스를 이용하고자 하는 고객은 당 사이트에서 정한 회원가입양식에 개인정보를 기재하여 가입을 하여야 합니다.
제 7 조 (개인정보의 보호 및 사용)
당 사이트는 관계법령이 정하는 바에 따라 회원 등록정보를 포함한 회원의 개인정보를 보호하기 위해 노력합니다. 회원 개인정보의 보호 및 사용에 대해서는 관련법령 및 당 사이트의 개인정보 보호정책이 적용됩니다.
제 8 조 (이용 신청의 승낙과 제한)
① 당 사이트는 제6조의 규정에 의한 이용신청고객에 대하여 서비스 이용을 승낙합니다.
② 당 사이트는 아래사항에 해당하는 경우에 대해서 승낙하지 아니 합니다.
- 이용계약 신청서의 내용을 허위로 기재한 경우
- 기타 규정한 제반사항을 위반하며 신청하는 경우
제 9 조 (회원 ID 부여 및 변경 등)
① 당 사이트는 이용고객에 대하여 약관에 정하는 바에 따라 자신이 선정한 회원 ID를 부여합니다.
② 회원 ID는 원칙적으로 변경이 불가하며 부득이한 사유로 인하여 변경 하고자 하는 경우에는 해당 ID를
해지하고 재가입해야 합니다.
③ 기타 회원 개인정보 관리 및 변경 등에 관한 사항은 서비스별 안내에 정하는 바에 의합니다.
제 3 장 계약 당사자의 의무
제 10 조 (KISTI의 의무)
① 당 사이트는 이용고객이 희망한 서비스 제공 개시일에 특별한 사정이 없는 한 서비스를 이용할 수 있도록
하여야 합니다.
② 당 사이트는 개인정보 보호를 위해 보안시스템을 구축하며 개인정보 보호정책을 공시하고 준수합니다.
③ 당 사이트는 회원으로부터 제기되는 의견이나 불만이 정당하다고 객관적으로 인정될 경우에는 적절한 절차를
거쳐 즉시 처리하여야 합니다. 다만, 즉시 처리가 곤란한 경우는 회원에게 그 사유와 처리일정을 통보하여야
합니다.
제 11 조 (회원의 의무)
① 이용자는 회원가입 신청 또는 회원정보 변경 시 실명으로 모든 사항을 사실에 근거하여 작성하여야 하며,
허위 또는 타인의 정보를 등록할 경우 일체의 권리를 주장할 수 없습니다.
② 당 사이트가 관계법령 및 개인정보 보호정책에 의거하여 그 책임을 지는 경우를 제외하고 회원에게 부여된
ID의 비밀번호 관리소홀, 부정사용에 의하여 발생하는 모든 결과에 대한 책임은 회원에게 있습니다.
③ 회원은 당 사이트 및 제 3자의 지적 재산권을 침해해서는 안 됩니다.
제 4 장 서비스의 이용
제 12 조 (서비스 이용 시간)
① 서비스 이용은 당 사이트의 업무상 또는 기술상 특별한 지장이 없는 한 연중무휴, 1일 24시간 운영을
원칙으로 합니다. 단, 당 사이트는 시스템 정기점검, 증설 및 교체를 위해 당 사이트가 정한 날이나 시간에
서비스를 일시 중단할 수 있으며, 예정되어 있는 작업으로 인한 서비스 일시중단은 당 사이트 홈페이지를
통해 사전에 공지합니다.
② 당 사이트는 서비스를 특정범위로 분할하여 각 범위별로 이용가능시간을 별도로 지정할 수 있습니다. 다만
이 경우 그 내용을 공지합니다.
제 13 조 (홈페이지 저작권)
① NDSL에서 제공하는 모든 저작물의 저작권은 원저작자에게 있으며, KISTI는 복제/배포/전송권을 확보하고
있습니다.
② NDSL에서 제공하는 콘텐츠를 상업적 및 기타 영리목적으로 복제/배포/전송할 경우 사전에 KISTI의 허락을
받아야 합니다.
③ NDSL에서 제공하는 콘텐츠를 보도, 비평, 교육, 연구 등을 위하여 정당한 범위 안에서 공정한 관행에
합치되게 인용할 수 있습니다.
④ NDSL에서 제공하는 콘텐츠를 무단 복제, 전송, 배포 기타 저작권법에 위반되는 방법으로 이용할 경우
저작권법 제136조에 따라 5년 이하의 징역 또는 5천만 원 이하의 벌금에 처해질 수 있습니다.
제 14 조 (유료서비스)
① 당 사이트 및 협력기관이 정한 유료서비스(원문복사 등)는 별도로 정해진 바에 따르며, 변경사항은 시행 전에
당 사이트 홈페이지를 통하여 회원에게 공지합니다.
② 유료서비스를 이용하려는 회원은 정해진 요금체계에 따라 요금을 납부해야 합니다.
제 5 장 계약 해지 및 이용 제한
제 15 조 (계약 해지)
회원이 이용계약을 해지하고자 하는 때에는 [가입해지] 메뉴를 이용해 직접 해지해야 합니다.
제 16 조 (서비스 이용제한)
① 당 사이트는 회원이 서비스 이용내용에 있어서 본 약관 제 11조 내용을 위반하거나, 다음 각 호에 해당하는
경우 서비스 이용을 제한할 수 있습니다.
- 2년 이상 서비스를 이용한 적이 없는 경우
- 기타 정상적인 서비스 운영에 방해가 될 경우
② 상기 이용제한 규정에 따라 서비스를 이용하는 회원에게 서비스 이용에 대하여 별도 공지 없이 서비스 이용의
일시정지, 이용계약 해지 할 수 있습니다.
제 17 조 (전자우편주소 수집 금지)
회원은 전자우편주소 추출기 등을 이용하여 전자우편주소를 수집 또는 제3자에게 제공할 수 없습니다.
제 6 장 손해배상 및 기타사항
제 18 조 (손해배상)
당 사이트는 무료로 제공되는 서비스와 관련하여 회원에게 어떠한 손해가 발생하더라도 당 사이트가 고의 또는 과실로 인한 손해발생을 제외하고는 이에 대하여 책임을 부담하지 아니합니다.
제 19 조 (관할 법원)
서비스 이용으로 발생한 분쟁에 대해 소송이 제기되는 경우 민사 소송법상의 관할 법원에 제기합니다.
[부 칙]
1. (시행일) 이 약관은 2016년 9월 5일부터 적용되며, 종전 약관은 본 약관으로 대체되며, 개정된 약관의 적용일 이전 가입자도 개정된 약관의 적용을 받습니다.